Related Experiment Video

Updated: Feb 24, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Primary Thrombophilia in México XI: Activated Protein C Resistance Phenotypes are Multifactorial

Ma Fernanda Vallejo-Villalobos1,2, Andrés León-Peña1,3,4, Mónica León-González1,2,4

  • 1Laboratorios Clínicos de Puebla, Puebla, Mexico.

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|August 22, 2017
PubMed

Insights

Activated protein C resistance (aPCR) phenotypes are common in Mexican Mestizos with thrombosis. Factor V Leiden mutation and direct oral anticoagulants (DOACs) are significantly associated with abnormal aPCR, impacting thrombophilia diagnosis.

Area of Science:

  • Hematology
  • Thrombosis Research
  • Clinical Diagnostics

Background:

  • Activated protein C resistance (aPCR) phenotypes are observed in approximately 20% of Mexican Mestizos presenting with thrombosis and thrombophilia markers.
  • Prospective study of 96 Mexican Mestizos with a history of thrombosis and primary thrombophilic state markers over 276 months.

Purpose of the Study:

  • To identify thrombophilic conditions in Mexican Mestizos with abnormal aPCR phenotypes.
  • To investigate associations between abnormal aPCR and specific thrombotic risk factors, including medication use.

Main Methods:

  • Prospective evaluation of 96 Mexican Mestizos with thrombosis and thrombophilia markers.
  • Laboratory assessment for abnormal aPCR phenotypes, Factor V Leiden mutation, Factor VIII levels, antiphospholipid antibodies, and lupus anticoagulant.
  • Recording of recent direct oral anticoagulant (DOAC) use.

Main Results:

  • An abnormal aPCR phenotype was identified in 18 individuals (18.75%).
  • Significant associations were found between abnormal aPCR and Factor V Leiden mutation (p=0.0022) and between abnormal aPCR and DOAC use (p=0.006).
  • Antiphospholipid antibodies and lupus anticoagulant showed a strong association (p<0.0001).
  • Direct oral anticoagulants (DOACs) were used by 22% of individuals with abnormal aPCR.

Conclusions:

  • Factor V Leiden mutation and recent DOAC use are significantly associated with abnormal aPCR phenotypes in Mexican Mestizos with thrombosis.
  • Laboratory evaluations for thrombosis etiology should consider recent DOAC use, as it can influence aPCR testing.
  • Findings align with international observations, reinforcing the need for comprehensive thrombophilia workups.
Keywords:
Protein CResistanceThrombophilia

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.8K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27
X-linked Traits01:19

X-linked Traits

In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
59.1K